The Haavind Pharma Report Summer 2020
Haavind’s Pharma Report is a retrospective report on legal developments in Norway relevant for the pharmaceutical sector and focuses on relevant developments within regulatory affairs and intellectual property. Since 2016, we have published the report twice a year, and we are pleased once again to present some of the significant legal developments that occurred during the first half of 2020.
Haavind’s Pharma Report is a retrospective report on legal developments in Norway relevant for the pharmaceutical sector and focuses on relevant developments within regulatory affairs and intellectual property. Since 2016, we have published the report twice a year, and we are pleased once again to present some of the significant legal developments that occurred during the first half of 2020.
In the Summer 2020 edition, we take a closer look on the Norwegian government’s proposal to allow pharmacies to substitute biological medicinal products. The report also takes a closer look at the new rules on advertising of medicinal products which recently entered into force, as well as many other interesting developments.
Earlier this year, Haavind also arranged a breakfast seminar on the opportunities and challenges in commercialization of Big Data for the healthcare sector, which we held in collaboration with the Danish data analyst and service provider DLIMI. A brief summary of the seminar is available in the report.Download the Pharma Report Summer 2020 here
